COLORADO SPRINGS, Colo., Feb. 28, 2014 /PRNewswire/ -- (OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announces it has been in confidential negotiations for several months with key players in Spain to expand into the Spanish market to conduct cannabis research and other operations. The initial agreement has been signed and more information will be provided. Spain's population is approximately 47 million and has a significant cannabis and hemp market.
"Market expansion both inside the United States and internationally is part of our strategic plan over the next three years. The Spanish market is harmonious with our research goals, and we are optimistic that significant announcements regarding Cannabis Science in Spain will be forthcoming on the heels of Spannabis 2014," stated Mario Lap, President of European Operations, Cannabis Science.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
SOURCE Cannabis Science, Inc.